Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004201 | 0.84 | GSK3B (0.51) | FGFR1FGFR2AXLPDPK1JAK2 | |
| SCHEMBL922069 | 0.81 | PDPK1 (0.65) | FGFR1FGFR2AXLPDPK1JAK2 | |
| SCHEMBL1573990 | 0.78 | MAP2K4 (0.58) | FGFR1FGFR2PDPK1HSP90AB1FGFR3 | |
| SCHEMBL30016013 | 0.76 | PDPK1 (0.63) | FGFR1FGFR2AXLPDPK1JAK2 | |
| SCHEMBL2955244 | 0.76 | MAP2K4 (0.55) | FGFR1FGFR2PDPK1HSP90AB1FGFR3 | |
| SCHEMBL2302544 | 0.76 | PDPK1 (0.63) | FGFR1FGFR2AXLPDPK1JAK2 | |
| SCHEMBL14755254 | 0.76 | AXL (0.49) | FGFR1FGFR2AXLPDPK1JAK2 | |
| SCHEMBL2926172 | 0.76 | AXL (0.49) | FGFR1FGFR2AXLPDPK1JAK2 | |
| SCHEMBL588513 | 0.76 | AXL (0.50) | FGFR1FGFR2AXLPDPK1JAK2 | |
| SCHEMBL29613696 | 0.76 | AXL (0.50) | FGFR1FGFR2AXLPDPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | FGFR1 2424/4885FGFR2 3823/4885AXL 974/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | FGFR1 2424/4885FGFR2 3823/4885AXL 974/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | FGFR1 144/4885FGFR2 467/4885AXL 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.